Table 1.
Baseline demographics of the treat‐to‐target and usual care study populationsa
| Treat‐to‐target (n = 246) | Usual care (n = 286) | Standardized differences | |||
|---|---|---|---|---|---|
| No. | Value | No. | Value | ||
| Age, years | 240 | 57.0 ± 12.8 | 271 | 58.0 ± 13.1 | 0.08 |
| Female, no. (%) | 246 | 196 (79) | 286 | 224 (79) | 0.01 |
| Hispanic, no. (%) | 210 | 47 (22) | 219 | 18 (8) | 0.40 |
| Race, no. (%) | |||||
| White | 206 | 181 (88) | 250 | 224 (90) | 0.06 |
| African American | 206 | 15 (7) | 250 | 14 (6) | 0.07 |
| Asian | 206 | 3 (2) | 250 | 3 (1) | 0.02 |
| Other/mixed | 206 | 7 (3) | 250 | 9 (4) | 0.01 |
| College educated, no. (%) | 236 | 133 (56) | 277 | 160 (58) | 0.03 |
| Part‐ or full‐time employment, no. (%) | 243 | 119 (49) | 280 | 141 (50) | 0.03 |
| Insurance, no. (%) | |||||
| Private | 224 | 168 (75) | 264 | 202 (77) | 0.04 |
| Medicare | 224 | 60 (27) | 264 | 86 (33) | 0.13 |
| Medicaid | 224 | 18 (8) | 264 | 12 (5) | 0.14 |
| No insurance | 224 | 10 (5) | 264 | 9 (3) | 0.05 |
| RA characteristics | |||||
| Disease duration, years | 245 | 7.3 ± 9.5 | 282 | 8.4 ± 9.4 | 0.12 |
| RF seropositivity, no. (%) | 184 | 124 (67) | 207 | 153 (74) | 0.14 |
| HAQ DI (0–3) | 234 | 1.1 ± 0.7 | 266 | 1.0 ± 0.7 | 0.07 |
| Disease activity | |||||
| CDAI (0–76) | 246 | 26.7 ± 13.4 | 286 | 25.5 ± 11.8 | 0.09 |
| CDAI disease activity category, no. (%) | |||||
| Moderate (CDAI >10 to ≤22) | 246 | 121 (49) | 286 | 139 (49) | 0.01 |
| High (CDAI >22) | 246 | 125 (51) | 286 | 147 (51) | 0.01 |
| TJC (0–28) | 246 | 8.0 ± 7.0 | 286 | 7.8 ± 5.5 | 0.03 |
| SJC (0–28) | 246 | 8.1 ± 5.6 | 286 | 7.3 ± 5.1 | 0.14 |
| ESR, mm/hour | 211 | 28.5 ± 24.9 | 240 | 29.8 ± 23.8 | 0.05 |
| CRP, mg/dl | 72 | 32.6 ± 83.7 | 166 | 24.6 ± 87.8 | 0.09 |
| Medication, no. (%) | |||||
| Biologic agent naive | 246 | 140 (57) | 286 | 158 (55) | 0.03 |
| Current glucocorticoid | 246 | 92 (37) | 286 | 103 (36) | 0.03 |
| Current biologic agent/small moleculeb | 246 | 54 (22) | 286 | 79 (28) | 0.13 |
| Current csDMARDsc | 246 | 85 (35) | 286 | 120 (42) | 0.15 |
| Current MTX | 246 | 165 (67) | 286 | 186 (65) | 0.04 |
a
Values are the mean ± SD unless indicated otherwise. RA = rheumatoid arthritis; RF = rheumatoid factor; HAQ DI = Health Assessment Questionnaire Disability Index score; CDAI = Clinical Disease Activity Index score; TJC = tender joint count; SJC = swollen joint count; ESR = erythrocyte sedimentation rate; CRP = C‐reactive protein; csDMARDs = conventional synthetic disease‐modifying antirheumatic drugs; MTX = methotrexate.
b
All patients undergoing treatment with a biologic agent or small molecule, with or without concurrent use of csDMARDs, at enrollment.
c
Patients treated with csDMARDs without a concurrent biologic agent or small molecule at enrollment.